TSC2 and prostate carcinoma: First, the genes that showed metastatic enrichment across multiple cancers (TP53, CDKN2A, and TERT) and genes that had a significant frequency bias in at least one metastatic cancer type (Amplification/Deletion/Mutation: AR‐prostate cancer; CCND1 and RSF1‐skin melanoma; CREBBP and TSC2‐pancreatic neuroendocrine tumor; ESR1‐breast cancer; PTEN‐prostate cancer; PTPRD‐kidney clear cell carcinoma, and RET‐thyroid) were selected [16].